Northwestern Mutual Wealth Management
GALT icon

Northwestern Mutual Wealth Management’s Galectin Therapeutics GALT Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.26K Buy
1,885
+1,285
+214% +$3.91K ﹤0.01% 3294
2025
Q4 		$2.5K Buy
+600
New +$3.16K ﹤0.01% 3423

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northwestern Mutual Wealth Management's GALT Position: Q1 2026 in Review

Northwestern Mutual Wealth Management increased its Galectin Therapeutics (GALT) stake by 214% in Q1 2026, buying an estimated $3.91K and bringing the position to 1,885 shares worth $5.26K. The position accounts for ﹤0.01% of the portfolio, ranked #3294.

Northwestern Mutual Wealth Management first reported a position in GALT in Q4 2025 and has held it in 2 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Northwestern Mutual Wealth Management held 1,885 shares of Galectin Therapeutics worth $5.26K as of Q1 2026.
  • Northwestern Mutual Wealth Management bought 1,285 Galectin Therapeutics shares in Q1 2026, an estimated $3.91K.
  • Galectin Therapeutics made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q1 2026, its #3294 holding.
  • Northwestern Mutual Wealth Management first reported a position in Galectin Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.